Skip to main content

Yesterday, Nov. 18, 2015, 127 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $235.29 to $228,091,773.00.

Highlighted Stocks Traded by Insiders:

Globus Medical (GMED) - FREE Research Report

Murphy A Brett, who is Group President, Commerical Op at Globus Medical, sold 5,000 shares at $25.80 on Nov. 18, 2015. Following this transaction, the Group President, Commerical Op owned 116,217 shares meaning that the stake was reduced by 4.12% with the 5,000-share transaction.

The shares most recently traded at $25.86, up $0.06, or 0.23% since the insider transaction. Historical insider transactions for Globus Medical go as follows:

  • 4-Week # shares sold: 1.9 million
  • 12-Week # shares sold: 1.9 million
  • 24-Week # shares sold: 1.9 million

The average volume for Globus Medical has been 589,300 shares per day over the past 30 days. Globus Medical has a market cap of $1.8 billion and is part of the health care sector and health services industry. Shares are up 10.01% year-to-date as of the close of trading on Wednesday.

Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. It offers products that address an array of spinal pathologies, anatomies, and surgical approaches. The company has a P/E ratio of 24.1. Currently, there are 9 analysts who rate Globus Medical a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GMED - FREE

TheStreet Quant Ratings

rates Globus Medical as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Globus Medical Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Investment Technology Group (ITG) - FREE Research Report

Marrale Michael, who is Managing Director at Investment Technology Group, sold 10,684 shares at $19.96 on Nov. 18, 2015. Following this transaction, the Managing Director owned 99,494 shares meaning that the stake was reduced by 9.7% with the 10,684-share transaction.

The shares most recently traded at $20.07, up $0.11, or 0.55% since the insider transaction. Historical insider transactions for Investment Technology Group go as follows:

  • 4-Week # shares bought: 300
  • 4-Week # shares sold: 2,564
  • 12-Week # shares bought: 300
  • 12-Week # shares sold: 2,564
  • 24-Week # shares bought: 15,800
  • 24-Week # shares sold: 2,564

The average volume for Investment Technology Group has been 528,200 shares per day over the past 30 days. Investment Technology Group has a market cap of $657.9 million and is part of the financial sector and financial services industry. Shares are down 2.64% year-to-date as of the close of trading on Wednesday.

Investment Technology Group, Inc. operates as an independent execution and research broker in the United States, Canada, Europe, and Asia Pacific regions. The stock currently has a dividend yield of 1.43%. The company has a P/E ratio of 31.6. Currently, there are no analysts who rate Investment Technology Group a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Recommends

Exclusive Offer: Get the latest Stock Analysis on ITG - FREE

TheStreet Quant Ratings

rates Investment Technology Group as a

hold

. The company's strongest point has been its very decent return on equity which we feel should persist. At the same time, however, we also find weaknesses including deteriorating net income, poor profit margins and a generally disappointing performance in the stock itself. Get the full

Investment Technology Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

LendingTree (TREE) - FREE Research Report

Patel Nikul, who is Chief Operating Officer at LendingTree, sold 2,000 shares at $117.10 on Nov. 18, 2015. Following this transaction, the Chief Operating Officer owned 31,412 shares meaning that the stake was reduced by 5.99% with the 2,000-share transaction.

The shares most recently traded at $104.61, down $12.49, or 11.94% since the insider transaction. Historical insider transactions for LendingTree go as follows:

  • 4-Week # shares bought: 400
  • 4-Week # shares sold: 125,000
  • 12-Week # shares bought: 400
  • 12-Week # shares sold: 125,000
  • 24-Week # shares bought: 400
  • 24-Week # shares sold: 140,000

The average volume for LendingTree has been 358,200 shares per day over the past 30 days. LendingTree has a market cap of $1.3 billion and is part of the financial sector and real estate industry. Shares are up 128.61% year-to-date as of the close of trading on Wednesday.

LendingTree, Inc., through its subsidiaries, operates an online loan marketplace for consumers seeking an array of loan types and other credit-based offerings in the United States. The company operates in four segments: Lending, Auto, Education, and Home Services. The company has a P/E ratio of 67.1. Currently, there are 4 analysts who rate LendingTree a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TREE - FREE

TheStreet Quant Ratings

rates LendingTree as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, compelling growth in net income, good cash flow from operations and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full

LendingTree Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.